Abbott Laboratories closed 10.57% short of its 52-week high of $141.23, which the company reached on March 4th.

Abbott Laboratories' medical device business is executing well, with double-digit growth in structural heart and diabetes.

The decision to allow a new trial could have  implications for both the companies and families with babies born prematurely.

Infant formula makers Abbott and Reckitt saw their stocks decline Friday after a judge ruled plaintiffs could pursue a new ...

Today, Benzinga 's options scanner spotted 10 uncommon options trades for Abbott Laboratories. This isn't normal. The overall ...

A Missouri judge has ordered Abbott Laboratories and Reckitt Benckiser unit Mead Johnson to face a new trial over allegations ...

Abbott Laboratories is undervalued with strong growth in diabetes care and weight-loss markets. Discover why ABT stock is a ...

We recently published a list of Friday’s 10 Worst Performing Stocks. In this article, we are going to take a look at where ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

ABT's shares rise on the back of its diversified business portfolio. However, the unfavorable macroeconomic scenario is concerning.

Whales with a lot of money to spend have taken a noticeably bullish stance on Abbott Laboratories. If we consider the ...

In the last year, many Abbott Laboratories ( NYSE:ABT ) insiders sold a substantial stake in the company which may ...